within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07D_Antipropulsives.A07DA53_LoperamideCombinations;

model LoperamideCombinations
  extends Pharmacolibrary.Drugs.ATC.A.A07DA53;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A07DA53</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Loperamide, in combination with other agents, is an antidiarrheal medication used to manage symptoms of acute or chronic diarrhea. It acts as a peripherally acting μ-opioid receptor agonist, reducing intestinal motility and prolonging transit time. Loperamide combinations are commonly used for symptomatic relief and are still approved and in use today globally.</p><h4>Pharmacokinetics</h4><p>No specific pharmacokinetic parameters for loperamide in combination products (ATC A07DA53) found in the literature for healthy adults or population subgroups.</p><h4>References</h4><ol><li><p>Kamali, F, &amp; Huang, ML (1996). Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. <i>British journal of clinical pharmacology</i> 41(2) 125–128. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1996.tb00169.x\">10.1111/j.1365-2125.1996.tb00169.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8838438/\">https://pubmed.ncbi.nlm.nih.gov/8838438</a></p></li><li><p>Dean, RL, et al., &amp; Deaver, DR (2012). Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. <i>Pharmacology, biochemistry, and behavior</i> 100(3) 530–537. DOI:<a href=\"https://doi.org/10.1016/j.pbb.2011.10.019\">10.1016/j.pbb.2011.10.019</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22056608/\">https://pubmed.ncbi.nlm.nih.gov/22056608</a></p></li><li><p>Griffith, JI, et al., &amp; Elmquist, WF (2022). Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity. <i>The Journal of pharmacology and experimental therapeutics</i> 380(1) 34–46. DOI:<a href=\"https://doi.org/10.1124/jpet.121.000821\">10.1124/jpet.121.000821</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34663676/\">https://pubmed.ncbi.nlm.nih.gov/34663676</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LoperamideCombinations;
